BEVERLY HILLS, CA, USA I October 23, 2014 I Rich Pharmaceuticals, Inc. (RCHA) (“Rich” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). Rich plans to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients. According to the American Cancer Society surveillance research group in 2014, it is estimated there will be 18,860 new cases of AML and 10,460 deaths from acute myeloid leukemia (AML) in the United States. Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow.

“We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS,” said Ben Chang, Chief Executive Officer. Rich submitted the IND for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS.

About Rich Pharmaceuticals:

Rich Pharmaceuticals, Inc. (RCHA) is a Biopharmaceutical Company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. Rich Pharmaceuticals’ goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals’ primary development stage product candidate which is known as RP-323 is being designed to treat blood and cancer related diseases through none evasive outpatient facilities. Find out more at www.richpharmaceuticals.com.

SOURCE: Rich Pharmaceuticals